Additional antibiotic lock in peritoneal dialysis-associated refractory peritonitis: A case series study and literature survey.

IF 1.1 4区 医学 Q3 UROLOGY & NEPHROLOGY
Weijing Lai, Bo Wang, Ruoxi Liao, Ping Fu, Hui Zhong
{"title":"Additional antibiotic lock in peritoneal dialysis-associated refractory peritonitis: A case series study and literature survey.","authors":"Weijing Lai,&nbsp;Bo Wang,&nbsp;Ruoxi Liao,&nbsp;Ping Fu,&nbsp;Hui Zhong","doi":"10.5414/CN111004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Refractory peritonitis is one of the leading causes of catheter failure in peritoneal dialysis (PD) patients. However, there are no established curative therapies available, and only catheter removal should be performed. Here we present a case series study to illustrate the efficacy of antibiotic lock for PD-associated refractory peritonitis.</p><p><strong>Materials and methods: </strong>Patients with refractory peritonitis treated with intraperitoneal antibiotics plus antibiotic lock from September 2020 to March 2022 were retrospectively analyzed. Medical cure was identified as a success of treatment.</p><p><strong>Results: </strong>We identified 11 patients, of which 7 (63.64%) had a history of PD-associated peritonitis, with the episode of continuous ambulatory peritoneal dialysis (CAPD) ranging from 1 to 158 months at a median of 36 (9.5, 50.5) months. The dialysis effluent culture showed Gram-positive, Gram-negative bacteria, and was culture-negative in 5, 2, and 4 cases, respectively. The cure rates were 85.71% for culture-positive cases and 25% for culture-negative cases, and the total cure rate was 63.64%. No relevant adverse events occurred, including sepsis.</p><p><strong>Conclusions: </strong>Treatment with the additional antibiotic lock was successful in most cases, especially in those that were culture-positive. Additional antibiotic lock deserves great attention and further investigation in treating PD-associated refractory peritonitis.</p>","PeriodicalId":10396,"journal":{"name":"Clinical nephrology","volume":"100 1","pages":"12-18"},"PeriodicalIF":1.1000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CN111004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Refractory peritonitis is one of the leading causes of catheter failure in peritoneal dialysis (PD) patients. However, there are no established curative therapies available, and only catheter removal should be performed. Here we present a case series study to illustrate the efficacy of antibiotic lock for PD-associated refractory peritonitis.

Materials and methods: Patients with refractory peritonitis treated with intraperitoneal antibiotics plus antibiotic lock from September 2020 to March 2022 were retrospectively analyzed. Medical cure was identified as a success of treatment.

Results: We identified 11 patients, of which 7 (63.64%) had a history of PD-associated peritonitis, with the episode of continuous ambulatory peritoneal dialysis (CAPD) ranging from 1 to 158 months at a median of 36 (9.5, 50.5) months. The dialysis effluent culture showed Gram-positive, Gram-negative bacteria, and was culture-negative in 5, 2, and 4 cases, respectively. The cure rates were 85.71% for culture-positive cases and 25% for culture-negative cases, and the total cure rate was 63.64%. No relevant adverse events occurred, including sepsis.

Conclusions: Treatment with the additional antibiotic lock was successful in most cases, especially in those that were culture-positive. Additional antibiotic lock deserves great attention and further investigation in treating PD-associated refractory peritonitis.

腹膜透析相关难治性腹膜炎的额外抗生素锁定:病例系列研究和文献调查。
背景:难治性腹膜炎是腹膜透析(PD)患者导管失效的主要原因之一。然而,目前还没有确定的治疗方法,只能进行导管拔除。在这里,我们提出了一个病例系列研究,以说明抗生素锁对pd相关性难治性腹膜炎的疗效。材料与方法:回顾性分析2020年9月至2022年3月期间应用腹腔内抗生素加抗生素锁药治疗的难治性腹膜炎患者。医学治愈被认为是治疗的成功。结果:我们确定了11例患者,其中7例(63.64%)有pd相关性腹膜炎病史,持续动态腹膜透析(CAPD)发作时间从1至158个月不等,中位时间为36个月(9.5,50.5)。透析出水培养革兰氏阳性菌5例,革兰氏阴性菌2例,革兰氏阴性菌4例。培养阳性病例治愈率为85.71%,培养阴性病例治愈率为25%,总治愈率为63.64%。未发生包括败血症在内的相关不良事件。结论:在大多数病例中,特别是那些培养阳性的病例,使用额外的抗生素锁治疗是成功的。在pd相关性难治性腹膜炎的治疗中,额外的抗生素锁值得重视和进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical nephrology
Clinical nephrology 医学-泌尿学与肾脏学
CiteScore
2.10
自引率
9.10%
发文量
138
审稿时长
4-8 weeks
期刊介绍: Clinical Nephrology appears monthly and publishes manuscripts containing original material with emphasis on the following topics: prophylaxis, pathophysiology, immunology, diagnosis, therapy, experimental approaches and dialysis and transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信